Semaglutide reduced major cardiovascular events by 26% in adults with type 2 diabetes at high cardiovascular risk

Munich, Germany, 16 September 2016 - Novo Nordisk today announced that semaglutide, an investigational glucagon-like peptide-1 (GLP-1) analogue administered once-weekly, significantly reduced the risk of the primary composite endpoint of time to first occurrence of either cardiovascular (CV) death, non-fatal myocardial infarction (heart attack) or non-fatal stroke by 26% vs placebo, when added to standard of care in 3,297 adults with type 2 diabetes at high CV risk.¹

These results were based on an accumulation of first major adverse CV events (MACE) in 254 people.¹

The main results from SUSTAIN 6 were presented today at the 52^nd Annual Meeting of the European Association for the Study of Diabetes (EASD) 2016² and also published in the New England Journal of Medicine.¹

References

1. Marso SP, Bain S, Consoli A, et al. Semaglutide and cardiovascular outcomes, efficacy and safety in type 2 diabetes. New England Journal of Medicine. 2016; In Press.

16 Sep 2016

Source: http://www.novonordisk.com/